Stock 002923 ZHUHAI RUNDU PHARMACEUTICAL CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Zhuhai Rundu Pharmaceutical Co., Ltd.

Equities

002923

CNE1000033G8

Pharmaceuticals

End-of-day quote Shenzhen S.E.
Other stock markets
 06:00:00 2024-04-29 pm EDT 		5-day change 1st Jan Change
10.86 CNY +1.78% Intraday chart for Zhuhai Rundu Pharmaceutical Co., Ltd. +5.95% -11.99%
Apr. 27 Zhuhai Rundu Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Apr. 27 Zhuhai Rundu Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 2,822 3,228 2,999 4,552 4,186 4,133
Enterprise Value (EV) 1 2,411 2,926 2,772 4,588 4,433 4,421
P/E ratio 25.8 x 27.2 x 21.8 x 32.2 x 26.9 x 61.7 x
Yield 2.55% 2.3% 2.48% 1.63% 2% -
Capitalization / Revenue 2.7 x 2.37 x 2.39 x 3.83 x 3.05 x 3.2 x
EV / Revenue 2.31 x 2.15 x 2.21 x 3.86 x 3.23 x 3.42 x
EV / EBITDA 19 x 21.5 x 15.6 x 23.1 x 18.8 x 20.9 x
EV / FCF -60 x -29.3 x -24.5 x -22.2 x -34.3 x -32.2 x
FCF Yield -1.67% -3.41% -4.07% -4.51% -2.92% -3.1%
Price to Book 3.24 x 3.43 x 2.89 x 4.09 x 3.5 x 3.71 x
Nbr of stocks (in thousands) 327,600 337,463 338,359 337,992 334,893 334,893
Reference price 2 8.615 9.566 8.863 13.47 12.50 12.34
Announcement Date 4/22/19 4/16/20 4/22/21 4/18/22 4/27/23 4/27/24
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 1,044 1,360 1,253 1,190 1,372 1,292
EBITDA 1 126.8 135.9 177.3 198.4 235.5 212
EBIT 1 95.38 98.31 127.3 138.5 166 142.6
Operating Margin 9.14% 7.23% 10.16% 11.64% 12.1% 11.04%
Earnings before Tax (EBT) 1 119.7 132.4 148.8 151.7 180.9 86.04
Net income 1 106.8 118.9 135.9 139.8 155.5 66.9
Net margin 10.24% 8.74% 10.85% 11.75% 11.33% 5.18%
EPS 2 0.3333 0.3516 0.4066 0.4176 0.4643 0.2000
Free Cash Flow 1 -40.22 -99.88 -113 -207 -129.2 -137.2
FCF margin -3.85% -7.34% -9.02% -17.4% -9.42% -10.62%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share 2 0.2198 0.2198 0.2198 0.2198 0.2500 -
Announcement Date 4/22/19 4/16/20 4/22/21 4/18/22 4/27/23 4/27/24
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - 36.2 247 288
Net Cash position 1 411 302 226 - - -
Leverage (Debt/EBITDA) - - - 0.1826 x 1.05 x 1.358 x
Free Cash Flow 1 -40.2 -99.9 -113 -207 -129 -137
ROE (net income / shareholders' equity) 15.7% 13.1% 13.7% 13% 13.5% 5.63%
ROA (Net income/ Total Assets) 6.46% 4.98% 5.6% 5.06% 4.95% 3.95%
Assets 1 1,653 2,385 2,425 2,764 3,143 1,695
Book Value Per Share 2 2.660 2.790 3.070 3.290 3.570 3.330
Cash Flow per Share 2 0.5600 0.5900 0.7400 0.7400 0.6600 0.6000
Capex 1 115 240 257 376 252 175
Capex / Sales 11.05% 17.65% 20.5% 31.64% 18.35% 13.51%
Announcement Date 4/22/19 4/16/20 4/22/21 4/18/22 4/27/23 4/27/24
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Pharmaceuticals

1st Jan change Capi.
ZHUHAI RUNDU PHARMACEUTICAL CO., LTD. Stock Zhuhai Rundu Pharmaceutical Co., Ltd.
-11.99% 502M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+26.08% 681B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+21.85% 556B
JOHNSON & JOHNSON Stock Johnson & Johnson
-4.77% 361B
MERCK & CO., INC. Stock Merck & Co., Inc.
+16.97% 325B
ABBVIE INC. Stock AbbVie Inc.
+5.69% 285B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.68% 235B
NOVARTIS AG Stock Novartis AG
+3.65% 199B
ROCHE HOLDING AG Stock Roche Holding AG
-11.12% 189B
PFIZER, INC. Stock Pfizer, Inc.
-3.40% 157B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 002923 Stock
  4. Financials Zhuhai Rundu Pharmaceutical Co., Ltd.